Hikma reiterates full year 2026 guidance following encouraging start to the year
Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading ahead of its Annual General Meeting.
Said Darwazah, Hikma’s CEO, said: “Our three businesses are performingwell, supported by our differentiated portfolio, recent product launchesand our strong and growing commercial capabilities. We continue to focus on strengthening our pipeline and today announced the signing of a device partnership for our inhalation platform, which will be a key growth driver for our Rx business. We are pleased with the performance of the Group and are on track to deliver revenue and profit growth, in line with our full ye...